Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2004 1
2005 1
2006 3
2007 3
2008 2
2009 2
2010 7
2011 6
2012 13
2013 14
2014 21
2015 29
2016 19
2017 9
2018 17
2019 16
2020 24
2021 18
2022 14
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25218297

200 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M. Lazcano-Ponce E, et al. Vaccine. 2014 Feb 3;32(6):725-32. doi: 10.1016/j.vaccine.2013.11.059. Epub 2013 Dec 16. Vaccine. 2014. PMID: 24355090 Clinical Trial.
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group. Safaeian M, et al. J Natl Cancer Inst. 2018 Feb 1;110(2):205-12. doi: 10.1093/jnci/djx158. J Natl Cancer Inst. 2018. PMID: 28954299 Free PMC article. Clinical Trial.
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M. Robbins HA, et al. Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811. Hum Vaccin Immunother. 2014. PMID: 25483632 Free PMC article.
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, De Muynck B, De Simoni S, Suryakiran P, Hezareh M, Folschweiller N, Thomas F, Struyf F. Leung TF, et al. Hum Vaccin Immunother. 2015;11(7):1689-702. doi: 10.1080/21645515.2015.1050570. Hum Vaccin Immunother. 2015. PMID: 26062002 Free PMC article. Clinical Trial.
Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G. Van Damme P, et al. Vaccine. 2014 Jun 17;32(29):3694-705. doi: 10.1016/j.vaccine.2014.03.040. Epub 2014 Mar 25. Vaccine. 2014. PMID: 24674663 Free article. Clinical Trial.
200 results